Olanzapine enabled rechallenge after lorlatinib‐induced psychosis: A case report
Abstract Background Lorlatinib is a third‐generation tyrosine kinase inhibitor for anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). While it has a high intracranial lesion control rate, it can also cause central nervous system complications, including psychotic symptoms....
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | PCN Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/pcn5.70091 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|